What after Paul Herendeen’s Insider Acquisition of Valeant Pharmaceuticals International, Inc. (VRX) Stock?; The Chefs' Warehouse, Inc. (CHEF) Had 5 Bulls

Company insider, Paul Herendeen, EVP and CFO of Valeant Pharmaceuticals International Inc purchased a total of 15,000 shares of the company, which is based on a stock price of $16.1 for each share. Presently, Paul Herendeen owns 231,492 shares which are equivalent to about 0.07% of the company’s market capitalization. Published March 13, 2018, you can read more about the trade by opening the following public 4F filing here.

Among 7 analysts covering Chefs’ Warehouse (NASDAQ:CHEF), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Chefs’ Warehouse had 26 analyst reports since July 31, 2015 according to SRatingsIntel. As per Wednesday, November 4, the company rating was upgraded by BB&T Capital. Canaccord Genuity maintained The Chefs' Warehouse, Inc. (NASDAQ:CHEF) on Thursday, October 5 with “Buy” rating. The stock of The Chefs' Warehouse, Inc. (NASDAQ:CHEF) earned “Buy” rating by Jefferies on Thursday, June 1. BMO Capital Markets maintained The Chefs' Warehouse, Inc. (NASDAQ:CHEF) rating on Wednesday, November 8. BMO Capital Markets has “Hold” rating and $18.0 target. The rating was maintained by Canaccord Genuity with “Buy” on Monday, August 28. The stock of The Chefs' Warehouse, Inc. (NASDAQ:CHEF) earned “Buy” rating by Canaccord Genuity on Friday, February 19. The firm has “Buy” rating by Loop Capital given on Friday, November 10. Jefferies maintained The Chefs' Warehouse, Inc. (NASDAQ:CHEF) rating on Monday, July 17. Jefferies has “Buy” rating and $1900 target. Canaccord Genuity maintained The Chefs' Warehouse, Inc. (NASDAQ:CHEF) rating on Thursday, November 9. Canaccord Genuity has “Buy” rating and $22.0 target. The firm has “Buy” rating given on Thursday, August 10 by Canaccord Genuity. See The Chefs' Warehouse, Inc. (NASDAQ:CHEF) latest ratings:

23/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $23.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $24.0 Maintain
13/11/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Upgrade
09/11/2017 Broker: Jefferies Rating: Buy New Target: $23.0 Maintain
10/11/2017 Broker: Loop Capital Rating: Buy Old Target: $21 New Target: $22 Maintain
08/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $18.0 Maintain
09/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/10/2017 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
05/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $20.0 Maintain

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 7 have Buy rating, 6 Sell and 15 Hold. Therefore 25% are positive. Valeant Pharmaceuticals Intl has $310 highest and $7.0 lowest target. $46.56’s average target is 189.55% above currents $16.08 stock price. Valeant Pharmaceuticals Intl had 159 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of VRX in report on Wednesday, November 11 with “Outperform” rating. RBC Capital Markets maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, March 16 with “Sector Perform” rating. IBC downgraded the stock to “Sector Perform” rating in Tuesday, October 20 report. The stock has “Hold” rating by RBC Capital Markets on Monday, October 2. The firm has “Hold” rating given on Monday, December 4 by BTIG Research. The company was downgraded on Thursday, November 10 by Rodman & Renshaw. The firm earned “Sell” rating on Friday, September 15 by Piper Jaffray. The firm has “Hold” rating given on Wednesday, March 2 by Canaccord Genuity. Mizuho downgraded the shares of VRX in report on Wednesday, November 23 to “Underperform” rating. The firm earned “Underperform” rating on Tuesday, June 20 by Mizuho.

Investors sentiment decreased to 0.97 in 2017 Q3. Its down 0.02, from 0.99 in 2017Q2. It dropped, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million shares in 2017Q2 were reported. Cornerstone Advsrs owns 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 160 shares. The Texas-based Dimensional Fund Advisors Lp has invested 0.03% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Brandywine Global Invest Management Llc has invested 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Fiera Corporation stated it has 0.03% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). State Of Wisconsin Invest Board holds 208,356 shares or 0.01% of its portfolio. Gabelli Funds Ltd Com owns 91,088 shares. Raymond James Services Advsr accumulated 74,106 shares or 0.01% of the stock. Horizon Kinetics Ltd Company has 0.01% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Old Mutual Customised Solutions (Proprietary) accumulated 11,900 shares. Intact Invest Mngmt reported 156,100 shares. Cap Mngmt Associate stated it has 0.25% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 300,000 were accumulated by Brigade Cap Management Lp. The Georgia-based Invesco Ltd has invested 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Ameriprise Financial holds 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 22,060 shares. Schroder Investment Management Gp Inc has 36,500 shares for 0% of their portfolio.

Since March 8, 2018, it had 1 insider buy, and 0 insider sales for $153,400 activity. DE SCHUTTER RICHARD U also bought $153,400 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Thursday, March 8.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $5.61 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 2.35 P/E ratio. Diversified Products.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 earnings per share, down 76.43% or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.22 million for 6.09 P/E if the $0.66 EPS becomes a reality. After $0.98 actual earnings per share reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65% negative EPS growth.

The stock increased 1.84% or $0.29 during the last trading session, reaching $16.08. About 8.60 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since March 14, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.

The ChefsÂ’ Warehouse, Inc., together with its subsidiaries, distributes specialty food products in the United States and Canada. The company has market cap of $663.16 million. The Company’s product portfolio includes approximately 43,000 stock-keeping units comprising specialty food products, such as artisan charcuterie, specialty cheeses, unique oils and vinegars, truffles, caviar, chocolate, and pastry products. It has a 42.91 P/E ratio. The firm also offers a line of center-of-the-plate products, including custom cut beef, seafood, and hormone-free poultry, as well as food products, such as cooking oils, butter, eggs, milk, and flour.